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Alzheimer's Disease and Down's Syndrome:
An Overview
Dr. Devanshu Desai, M.B.B.S.
The association between Alzheimer's Disease and Down 's Syndrome is well
recognized through clinical observations and genetic stu d ies. However, the
exact nature and the implications of this link is fa r from clear as yet. The
challenge of diagnosis, genetics and the differences in clinical present ations of
Alzheimer's Disease in relation to the Down's Syndrome are reviewed here.
Promising areas of research are pointed out and importance of relevant family
history is emphasized. A current knowledge in th e subject throug h various
stu d ies is presented.
INTRODUCTION
The association between Down's Syndrome [DS] and Alzheimer's Disease
[AD] has been well recognized for some time now. Senile plaq ues were first
described in DS brains in 1921 by Struwe. In 1948 J ervis described clinical
deterioration and Alzheimer's neuropathology in DS. It is also suggested now
that this association is two-sided! On one hand individua ls with DS tend to
develop AD at some point in th eir lives ifthey survive long enough (1-5). On the
other hand, there have been some reports of h igh er tha n expected frequencies
of DS in families with AD (5,6). More recently, a gene defect associated with the
" familial Alzheimer's Disease" (FAD) has been mapped to chromosome 21 , a
chromosome related to DS (7,8) . Although some of th ese find ings are disputed,
it is worthwhile to review current knowledge in th e relati onsh ip between these
two conditions, while awaiting further information abo ut clinicopathological
and genetic association between them.
T his overview describes each of these two conditions briefly in relation to
th e other and then examines th e association and th e implica tions of th is associa-
tion between them.
In this overview , th e term AD is used to refer to ind ividuals with a
prov isional diagnosis of Primary Degenerative Dementia of Alzheimer's type.
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Alzheimer's Disease-Diagnostic Accuracy
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Primary Degenerative Dementia-Alzheimer's type, is a neuropathological
diagnosis. It is the commonest cause of dementia in the general populatio n an d is
frequently encountered entity in clinical settings in individuals presenting wit h
symptoms of dementia. AD remains mainly a diagnosis of exclusion . Antemor-
tem diagnostic accuracy depends on variety of factors , including patient selec-
tion, diagnostic criteria and assessment methods. The postmortem histologica l
verification of the diagnosis is therefore the gold standard (9).
AD in persons with a normal karyotype usually begins with learning and
memory deficits, and slowly progresses to involve all the aspects of intellectual
activity including judgement, calculation and language (10). In the early stages,
psychometric assessment indicates more profound impairment of ideomotor
performance than language (10). Dalton et al (11) reported that memory loss,
depression and disorientation were the most frequently reported early sym p-
toms of AD in patients with a normal karyotype. In comparison, th ese are th e
least frequently reported symptoms in DS individuals who developed AD (11).
There have been several reports systematically describing functional and
clinical disturbances in AD in the general population and the reader is advised
here to refer to the relevant literature for a detailed description.
The differential diagnosis of dementia has remained a challenge. There are
several assessment methods now available which are reasonably sensiti ve and
specific in differentiating causes of dementia. Many investigators have used
behavioral observations (12), while the others have used sophisticated neurodiag-
nostic tools including Computed Tomography (CT), Positron Emission T omog-
raphy (PET), Single Photon Emission Computed Tomography (SPECT), Xenon
inhalation, Electroencephalography (EEG), Evoked potentials and combina tions
of these for the etiologic diagnosis of dementia (9). However because of factors
such as cost/benefit ratio, sensitivity, specificity and accessibil ity, these meth ods
have remained research tools at large. At present, there is no 'gold standard'
criterion or test for the determination of etiology of dementia in clinical settings.
The etiologic diagnosis of dementia is critical because some of th e o ther causes
are treatable or at least controllable to some extent.
As mentioned earlier, diagnostic accuracy of AD depends on a variety of
factors. Tiemay et al (13) reported that accuracy varied between 81 % and 88 % in
clinical settings. A retrospective review by Bolier et a l (14) and th e report of
Joachin et al (15) suggest that elaborate clinical investigations may not enhance
diagnostic accuracy. In research settings the diagnostic acc uracy may exceed
90 % (9). Morris et al (16) reported 100% accuracy in a selected sample of 31
cases with strict inclusion and exclusion criteria without any reference to
neuropsychological test performance. These findings app ly to th e general popu-
lation with normal or unknown karyotype, where, in ab sence of a 'gold stan-
dard' , the selection of a sample is extremely difficult. T he issue of d iagnost ic
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accuracy is much more difficult, particularly in the early stage of AD, in the
individuals with DS.
Genetics ofAD
A genetic basis for some cases of AD was first suggested in 1933 (17). There
are case reports describing ' familial Alzheimer's disease' [FAD] (18,19), charac-
terized by early onset dementia. Brietner et al in recent studies (20, 2 1) indicated
that the majority of these cases are inherited as an autosomal dominant muta-
tion. In a more recent study (22) they reported a striking increase in cum ula tive
incidence of AD-like illness among the first degree relatives of AD probands.
Bird et al (23) noted significant phenotypic heterogeneity in 180 demented
individuals from 24 kindreds. They noted clinical and neuropathological d iffer-
ences among families with AD. They raised questions whether th ere is more
than one type of AD, even among FAD patients and whether th e phen otypic
heterogeneity represents a genetic heterogeneity or is merely an epiphe nome-
non. St. George Hyslop et al (8) recently reported FAD linked to two chromo-
some 21 q21 loci in four families. One of these two markers is link ed to the
amyloid B gene. Thus the q21 region of the long arm of chromosom e 2 1 seems
to be of particular relevance to AD. Some groups of pedigrees have been
assembled in which autopsy determined AD appears to be inherited as an
autosomal dominant trait (24). However, the findings of genetic linkage were
disputed by Schellenberg et al (24). They found no evidence of linkage bet ween
FAD and chromosome 21 markers, including the am yloid B gene. T hey ob-
tained strong evidence for genetic heterogeneity when they compared their
study group to St. George Hyslop et aI's group. In this study, most of the
evidence for exclusion of genetic linkage came from presenile onset families ,
although the age of onset was higher than that in St. George Hyslop et aI's
group. They mentioned the possibility that the gene in chromosome 2 1 may
account only for very early onset FAD.
There also are some other results suggesting genetic involvement in AD .
From Heston et aI's careful genetic study (3) of 125 families, some relatives of
younger probands from autopsy proven AD appear to be at increased risk of
Down's syndrome, of myeloproliferative disorders and immune system d isor-
ders. Kallmann's (25) investigation oftwin pairs suggested monozygotic concor-
dance in AD. All these evidences suggest a genetic component in at least some
cases of AD. The exact nature of such genetic contribution is yet to be known.
Down's Syndrome
Ever since the classical description of 'Mongolism ' by Langdon Down in
1866, this has remained the most discussed and the most investigated syndrome
in the field of mental retardation. The presence of an extra small ch romosome
was reported by Lejeune in 1959, and was later identified as chromosome 21 .
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These patients present with a var iety of physical characte ris tics and clini cal
problems.
Only two decades ago, very few DS individuals survived through mid-
ad u lthood because of associated congenital heart disea se , recurrent infect ions
and a variety of other problems. With advancing health care an d medical
te chnology, more and more of these individuals surv ive until 40 years and
be yond. According to recent data by Baird and Sadovn ick (33), 80 % of DS
patients without congenital heart disease survive past th e age of 30 years. Mo re
than 50 % of their DS patients reached their 50 's and 13.5% reached age 68.
These observations are significant in relation to the development of AD neuro-
pathology in these individuals.
Studies have shown a higher than average incidence of hypoth yroid ism
(34-37), and at least average incidence, if not higher, of depression (38) in DS.
Hypothyroidism in DS is expressed usually as abnormality in one or mo re
thyroid function tests whereas clinically, most of these individuals are asymptom-
atic. Hollingworth et al (39) compared T4, T3 and TSH levels in 60 DS patients
to controls and did not find a significant difference. However, six DS patients
had goiter and seven had exophthalmos without goiter. Man i (40) studied 55
adult hospital DS patients; almost all of them were 40 yea rs or over. He found a
high frequency of clinical features suggesting hypothyroidi sm. He recom-
mended screening th yroid function in all DS individuals over 40.
In spite of the lack of evidence pointing to specific ca uses of hypothy-
roidism, some ha ve suggested autoimmunity as an etiologic facto r for underactiv-
ity of the th yroid gland (40) . Most of these stu d ies found antibo dies to thyroid
tissue in DS patients. Increased rates of lymphocytic leukemia and other malig-
nancie s and a higher incidence of viral and bacterial infections have also been
reported (41-43). A higher incidence of congenital hypothyroid ism had also
been reported (44).
In 1981 , Harrell et al (45) reported benefici al effects of vita mins, minerals
and th yroid compound in improving intellectual function ing in persons with DS.
They did not evaluate th yroid function prior to therapy. Subsequent att empts to
replicate these results with vitamin and mineral therapy were un successful (46).
Tiurosh and Toub et al (47), in a double blind cross-over drug-placebo trial,
stu d ied a small sample to assess the efficacy of short term th yroid supplement in
DS individuals with low borderline th yroid function. They found no significant
gains with thyroid supplement. Replication of similar results on a larger sample
with more attention towards symptoms of dementia is needed to clarify the
indications for thyroid supplement in DS individuals.
A high prevalence of psychiatric disorders in th e mentally retarded, includ-
ing those with DS, has been reported (48). Several case reports of major
depression in DS patients hav e been published (49 ,50), a lthoug h th ere have been
some unusual presentations and disagreements in th e d iagnosis of affective
disorders in moderate to severe retardation. Estimates of th e preva lence of
depression in DS are not availabl e at present. Considering menta lly re ta rded of
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all th e different etiologies as a single group, it seems like ly that affective
disorders are at least as common in th ese individuals as in general population
(38). This is particularly significant in DS pati ent over age of 40, sinc e it
complicates the detection of early AD .
Alzheimer's Disease in Down's Syndrome
Alongside the clinical observations and genetic stu d ies in AD patients, there
are several reports on DS individuals that sugges t a str iking association between
these two conditions. However, th e nature and th e clinical and genetic implica-
tions of this association remains elusive. Neuropathologica l cha nges of AD in
brains of DS individuals have been reported for more than 50 years now. Since
Struwe 's report in 1929, it is well recognized from severa l stu d ies that virtually
all DS individuals 37 years or over develop AD neuropathology, na mely, exten-
sive neurofibrillatory degeneration and senile plaques, throughout wides pread
regions of neocortex (26,27); Certain dermatoglyphic patterns are co mmon in
DS patients (28,29,30), and the extension of th ese stu dies to their parents
showed unusual combinations of dermatoglyphic patterns in parent s, particu-
larly in a parent in whom non-disjunction occurred (31) . Dermato glyph ic changes
sim ilar to DS were also observed in AD by Weinrab who repo rted a high
frequency of ulnar loops on fingertips of both AD and DS patients (32). These
and other evidences are becoming clearer as the surv ival of DS individuals is
prolonged.
Clinically, some investigators have observed differences in sympto ms of AD
in DS patients and in general population. Dalton et al (11) reviewed 35 DS cases
from several case reports. They examined 18 descriptive terms of fun ct ion al an d
clinical features in these cases excluding language based disturban ces. They
found that the most frequently reported c1inico-functional ex pression in these
cases was clinical seizures (87.8 %); followed by personality changes (45 .5%) and
focal neurological signs (45.5 %). The most frequently reported symptoms in
patients with AD in general population-i.e . memory loss, depression and
disorientation-were the least frequently reported in persons with AD in DS.
Besides, differences were noted in self help skills and level of activity in th ese two
groups with AD . Although such comparison between unmatch ed groups and
variable interpretations of retrospective clinical records can provide som e direc-
tion for further research , it serves little in clarifying the confusion regarding the
natural history of AD in DS.
Only one prospective study on AD in DS is reported in literature (5 1). In
this study of 49 clinically demented DS individuals over age 35 followed
longitudinally, the average age of dementia onset was 54.2 + 6.1 years, which is
much earlier than AD in the general population. In 23 patien ts who died, the
average duration was 4.6 + 3.2 years with no sign ificant difference between the
sexes. This study was also able to delineate severa l features of A D in the ir DS
patients. (i) The first signs of dementia in DS-changes in personal ity such as
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irritability and emotional labil ity in most cases in th eir study population-
correlate with the lat e features of AD in general populati on . (ii) There is a latent
period of 2 to 3 decades between the time of onset of neuropatho logica l changes
and clinical symptoms. (iii) Prevalence of dementia increases wit h age. (iv) There
is higher incidence of se izu res in th ese individuals as compared to AD patients in
general population . (v) T wenty percent of DS outpatients with dement ia a lso
developed Parkinson's disea se.
DISCUSSION
The available information about the association between A D and DS raises
many questions and hypotheses, most of which still remain unanswered . The
differences noted in clinical features of AD in DS and in persons with normal
karyotype poses a question if there is a different etiology and pathogen esis of AD
in these two groups (11). This questions the significance of pathological changes
and the clinicopathological correlation in AD. The issue is further complicated
by findings of changes identical to AD in many elderly brains in absence of
clinical symptoms. Interestingly enough, there are at lea st two case reports of DS
patients-one 49 years and the other 47 years of age-who showed no neuropa-
thology of AD in brain on autopsy (52,53). The prevalence of AD increases with
age in DS as well as general population and it is assumed that th e agin g process
begins early and progresses rapidly in DS individuals (54 ). These obse rvations
support Gowers' concept with the implication that AD represents merely a
precocious aging of central nervous system (55). If so, one can assume th at every
individual who lives long enough will develop AD at some point. It may be
possible that the symptoms appear only when brain changes are extensive
enough or when they involve certain brain areas, such as hippocampus.
However, from epidemiological evidence and clinical observations, there is
little doubt that a disease process is involved in AD. Besides th e issue of causal
factors it also remains to be seen if there are separate factors that control th e age
of onset in AD .
Almost all DS individuals show AD neuropathology at so me point , and up to
85 % of these-presumably all if they lived long enough-develop AD (5 1).
Theoretically it seems possible to detect AD in its early phase and to delineat e its
natural history in this cohort. In that case, the idea of detecting a " he ra ld sign"
that predicts or signals the onset of clinical AD appears promising. An individual
sign which increases in prevalence with advancing age ma y need careful scrut iny.
Examples of such signs would include primitive reflexes, face -hand te st etc., of
course, this would require several detailed longitudinal observati ons.
As mentioned earlier, there are strong indications of a genetic link between
AD and DS. Although a chromosomal abnormality in AD needs further confir-
mation, if present, it could be of tremendous help in screen ing potential parent s
with high risk pregnancies. For clinicians, it would be important to include
spec ific questions in obtaining the family history of individuals with these
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con di t io ns. In co n cl us io n, there is no d oubt about the rel a tio n sh ip between AD
a nd DS , but there are se ve ra l unanswered questio ns regarding the nature of this
relationship. The issu es of o r ig in , pathogenesis a nd the natural history of
dementia in DS awaits further prospective stud ies. The group of DS individuals
see m s a readily available " id ea l" co h o r t because of their a lmost certainly known
outcome. Obviously, this will be a promising area of research in the field of
ps ychiatry and the study of mental retardation .
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